Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development Bioprojet SCR Griffin Discoveries BV Johnson & Johnson Novartis AG Palau Pharma SA Sensorion SA Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles azasetron - Drug Profile Product Description Mechanism Of Action R&D Progress BPI-7881A - Drug Profile Product Description Mechanism Of Action R&D Progress GD-134 - Drug Profile Product Description Mechanism Of Action R&D Progress GD-136 - Drug Profile Product Description Mechanism Of Action R&D Progress GD-48 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-28610244 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress toreforant - Drug Profile Product Description Mechanism Of Action R&D Progress UR-63325 - Drug Profile Product Description Mechanism Of Action R&D Progress ZPL-389 - Drug Profile Product Description Mechanism Of Action R&D Progress Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones Featured News & Press Releases Feb 14, 2018: Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting Jan 24, 2018: Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting Sep 12, 2017: Sensorion’s Oral Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study Aug 22, 2017: Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients Jun 08, 2017: Sensorion Takes a Key Step towards Phase 2 with SENS-401 Thanks to the Positive Results Obtained in the Phase 1 Clinical Trial May 02, 2017: Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model Mar 09, 2017: Sensorion Receives European Authorization to Initiate Phase II Clinical Trial of SENS - 111 to Treat Acute Vertigo Feb 15, 2017: Sensorion Inner Ear Disease Product Candidates and Technology Subject of Multiple Presentations at ARO MidWinter Meeting 2017 Feb 15, 2017: Sensorion Presents Poster on its Drug Candidate, SENS-401, at Association for Research in Otolaryngology Annual Meeting Dec 14, 2016: Sensorion provides update on SENS-111 at ARO MidWinter Meeting 2017 Dec 14, 2016: Sensorion provides update on SENS-401 at ARO MidWinter Meeting 2017 Nov 24, 2016: Sensorion Receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss Nov 17, 2016: Sensorion Presents New Preclinical Results with SENS-401 in Acute Sensorineural Hearing Loss at Neuroscience 2016 Oct 17, 2016: Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe Oct 06, 2016: Sensorion presented data from the caloric test with SENS - 111 at the EACPT conference Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Bioprojet SCR, H1 2018 Pipeline by Griffin Discoveries BV, H1 2018 Pipeline by Johnson & Johnson, H1 2018 Pipeline by Novartis AG, H1 2018 Pipeline by Palau Pharma SA, H1 2018 Pipeline by Sensorion SA, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018